Apellis Pharmaceuticals Email Format
Biotechnology Research
・
501-1,000 employees
・
Waltham, MA, USA
Apellis Pharmaceuticals is a biotechnology company developing transformative therapies by targeting complement C3 to treat debilitating diseases across ophthalmology, nephrology, hematology, and neurology.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@apellis.com
Company Overview
Industry
Biotechnology Research
Founded
2008
Headquarters
Waltham, MA, USA
Revenue
$500M-$1B
FUNDING Stage
Public
Website
Key Executives
Cedric Francois (President and Chief Executive Officer), Timothy Sullivan (Chief Financial Officer), Nur Nicholson (Chief Technical Operations Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Apellis Pharmaceuticals?
Apellis Pharmaceuticals uses the first.last format, so Jane Smith would be jane.smith@apellis.com.
What approved products does Apellis Pharmaceuticals currently market?
Apellis Pharmaceuticals markets two approved products: SYFOVRE (pegcetacoplan injection) for geographic atrophy secondary to age-related macular degeneration, and EMPAVELI (pegcetacoplan) for PNH, C3G, and primary IC-MPGN, with both products generating combined net product revenue of $689 million in 2025.
How can I find and verify an Apellis Pharmaceuticals contact for outreach?
Since Apellis Pharmaceuticals follows the first.last@apellis.com email format, you can build and verify contacts using a tool like Clay, which lets you enrich a prospect list with confirmed email addresses and job titles for specific roles across the company.
Who co-founded Apellis Pharmaceuticals and when was the company established?
Apellis Pharmaceuticals was co-founded by Cedric Francois and Pascal Deschatelets, and the company was established in 2009. Cedric Francois went on to serve as President and Chief Executive Officer, with Pascal Deschatelets serving as Chief Scientific Officer.
Which therapeutic areas does Apellis Pharmaceuticals have active pipeline programs in beyond its approved products?
Beyond its approved ophthalmology and rare disease medicines, Apellis Pharmaceuticals has pipeline programs in neurology and is advancing gene-edited complement therapies and an oral complement inhibitor, all in preclinical stages, along with a pivotal Phase 2/3 study of EMPAVELI in focal segmental glomerulosclerosis.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating